<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://harvardscience.harvard.edu" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>all Stephen Soumerai stories</title>
 <link>http://harvardscience.harvard.edu/stories/person/1512</link>
 <description>Stories and external links referencing a person (RSS)</description>
 <language>en</language>
<item>
 <title>Value of direct-to-consumer drug advertising oversold, study finds</title>
 <link>http://harvardscience.harvard.edu/animal-vegetable-mineral/articles/value-direct-consumer-drug-advertising-oversold-study-finds</link>
 <description>&lt;!--paging_filter--&gt;&lt;p&gt;Direct-to-consumer advertising may not be giving big pharma such a big bang for their five billion bucks after all. Despite the billions spent on bringing drug marketing campaigns straight into patients’ living rooms, such strategies have a modest effect at best—and in some cases, no effect at all.&lt;/p&gt;&lt;p&gt;“People tend to think that if direct-to-consumer advertising wasn’t effective, pharma wouldn’t be doing it,” says Harvard Medical School professor &lt;a title=&quot;&quot; href=&quot;http://harvardscience.harvard.edu/directory/researchers/stephen-soumerai&quot;&gt;Stephen Soumerai&lt;/a&gt;, principal investigator on the study. “But as it turns out, decisions to market directly to consumers is based on scant data.”&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://harvardscience.harvard.edu/animal-vegetable-mineral/articles/value-direct-consumer-drug-advertising-oversold-study-finds&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <pubDate>Tue, 02 Sep 2008 13:00:58 -0400</pubDate>
 <dc:creator>404132862</dc:creator>
 <guid isPermaLink="false">20386 at http://harvardscience.harvard.edu</guid>
</item>
<item>
 <title>Hospital length of stay may not affect a newborn&#039;s health</title>
 <link>http://harvardscience.harvard.edu/medicine-health/articles/hospital-length-stay-may-not-affect-newborns-health</link>
 <description>&lt;!--paging_filter--&gt;&lt;p&gt;Researcher Jeanne M. Madden and colleagues used seven-and-a-half years of data on 20,366 mother-infant pairs with normal vaginal deliveries within a large Massachusetts health maintenance organization to determine the effects of reductions by the HMO in the postpartum length of stay and a subsequent state law establishing a minimum stay. The investigators measured the effects on lengths of hospital stay, follow-up care for newborns, use of outpatient care and hospital-based services during the first 10 days of life, and expenditures for hospital and home-based maternity services. &quot;Several studies have suggested that short stays are associated with an increased risk of death or readmission of the infant, whereas others have found no effect,&quot; Madden said. &quot;In the setting we studied, we found neither policy appeared to affect the health outcomes of newborns. But after coverage for longer stays was guaranteed by law, newborns were less likely to be examined as recommended on day 3 or 4.&quot; Funding for this study was provided by the Agency for Healthcare Research and Quality, the Harvard Pilgrim Health Care Foundation, and the Maternal and Child Health Bureau.&lt;/p&gt;
</description>
 <pubDate>Mon, 26 Mar 2007 05:27:52 -0400</pubDate>
 <dc:creator>70652986</dc:creator>
 <guid isPermaLink="false">3330 at http://harvardscience.harvard.edu</guid>
</item>
</channel>
</rss>
